Candy B, Jones L, Williams R, et al. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic ...

Results from a phase 3 clinical trial, recently published in The Lancet Oncology, present a significant breakthrough in the field of prostate cancer surgery. The NeuroSAFE technique, a novel approach ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

The results of the NeuroSAFE PROOF trial, presented at the 2025 European Association of Urology (EAU) Congress in Madrid and published in The Lancet Oncology, raise the prospect of major quality of ...

Wrapping dehydrated human amniotic membrane around nerve and anastomotic tissue during robotic prostatectomy was associated ...

No significant association found between phosphodiesterase type 5 inhibitor use and biochemical recurrence after radical treatment. Oral drugs to treat erectile dysfunction after radical treatment for ...

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

Low-intensity extracorporeal shock wave therapy (LI-SWT) did not improve erectile dysfunction compared to a sham procedure in radical prostatectomy patients. Fewer than 20% of men in the LI-SWT group ...

More than 80 percent of prostate cancer patients develop erectile dysfunction (ED), regardless of whether they have surgery or external radiation therapy, according to a recent study published in the ...

Testosterone testing and treatment have increased significantly over the past 2 decades, yet clinical practices remain inconsistent. 1,2 Despite rising awareness and prescription trends, up to 25% of ...

The results of the NeuroSAFE PROOF trial, presented at the 2025 European Association of Urology (EAU) Congress in Madrid and published in TheLancet Oncology, raise the prospect of major quality of ...